1.The study of application of the intra-aortic balloon pump in the patients with renal insufficiency during cardiac surgery
Chinese Journal of Thoracic and Cardiovascular Surgery 2013;29(9):522-524
Objective To discuss the protective effect of intra-aortic balloon pump(IABP) on renal function in patients with chronic renal insufficiency undergoing cardiac operations.Methods From May 2010 to May 2012,17 patients with moderate renal insufficiency who underwent cardiac surgery using cardiac pulmonary bypass(CPB) were randomized to divide into IABP group and control group.IABP was inserted before the cardiac operation,the support was maintained perioperatively in IABP group.In control group the IABP was never used during the operation.The clinical parameters related to renal function including the output of urine,the serum creatinine levels were documented perioperatively.Results The serum creatinine levels were increased obviously post-operation in both groups.But the degree of increase was significantly smaller in IABP group.Conclusion To patients with moderate renal insufficiency undergoing CPB cardiac operations,perioperative application of IABP is beneficial to protect renal function and may help to improve the outcome.
2.Clinical observation of acute kidney injury in patients after heart transplantation
Fenlong XUE ; Junwu CHAI ; Honglei CHEN ; Wei ZHOU ; Kai WANG ; Xiangrong KONG
Tianjin Medical Journal 2017;45(1):51-53
Objective To summarize the treatment experiences in patients with cardiac surgery-associated acute kidney injury (CSA-AKI). Methods The clinical data of 9 patients with acute renal injury after orthotopic heart transplantation in our hospital from January 2009 to July 2016 were retrospectively analyzed. Three patients were required the high-dose diuretics (furosemide, >80 mg/d) and six patients were received continuous renal replacement therapy (CRRT). The levels of serum creatinine (Cr) and estimated glomerular filtration rate (eGFR) were compared before and after heart transplantation and after the treatment of AKI. The quality of life was observed in patients in perioperative period. Results After the treatment of diuretics or CRRT, patients showed renal function recovery with significant decreased Cr levels and increased eGFR compared with the postoperation. The patients with diuretic therapy revealed a better eGFR recovery than those with CRRT. Conclusion CSA-AKI should be based on the severity of disease, and comprehensive treatment should be taken to reduce renal damage.
3.Study of Application of Coronary Endarterectomy in Coronary Artery Bypass Graft
Kai WANG ; Xiangrong KONG ; Yuxiang ZHU ; Jinshan WANG ; Wei ZHOU ; Honglei CHEN ; Junwu CHAI
Tianjin Medical Journal 2014;(8):814-817
Objective To study the application of coronary endarterectomy (CE) in coronary artery bypass graft (CABG), and to evaluate the effect of CE plus CABG on patients with chronic total occlusion (CTO) combined with diffuse distal atherosclerosis. Methods Thirty one patients, who underwent coronary endarterectomy in our institution between Oc-tober 2009 and October 2012, were reviewed retrospectively and compared the control group with 31 patients of their age, sex, LV function, and angina class. Results Among the 31 patients, 27 patients underwent one, 4 patient underwent two coronary arteries endarterectomized. Of all these 35 total endarterectomies, 13 (37%) were at left anterior descending artery, 3(9%) were at branches of the circumflex artery, and 19 (54%) involved the right coronary artery. There was no statistical dif-ference between two groups in clinical parameters including aorta cross time, cardiopulmonary bypass time, graft runoff, pul-sation index and mechanism ventilate time (P>0.05). There was no perioperative myocardial infarctions in CE group nor in control group. All patients were followed up and no recurrent angina were present in CE group. In CE group, one patient died of fungal pneumonia and heart failure half a year after operation. Conclusion In current cardiac surgical practice, coronary endarterectomy is an indispensable adjunct to CABG. The operative mortality and major morbidity were comparable or simi-lar to coronary artery bypass grafting, but its short-term and medium-term results were more favorable than to CABG.
4.Analysis of risk factors of new onset atrial fibrillation after on-pump coronary artery bypass grafting
Fenlong XUE ; Junwu CHAI ; Honglei CHEN ; Wei ZHOU ; Kai WANG ; Xiangrong KONG
Tianjin Medical Journal 2017;45(8):877-880
Objective To investigate the risk factors of postoperative atrial fibrillation (POAF) in patients with on-pump coronary artery bypass grafting (ONCAB). Methods The clinical data of 200 patients with ONCAB were retrospectively analyzed. The patients were divided into POAF group (n=52) and non POAF group (n=148) according to the occurrence of POAF after operation. The perioperative data including age and gender of all patients were collected and analyzed. The index of opinion of statistical results was classified by two categories Logistic regression analysis, and the related risk factors of POAF were analyzed. The receiver operating characteristic (ROC) curves of the age, red blood cell (RBC), left atrial diameter (LAD) and left ventricular ejection fraction (LVEF) were analyzed in two groups. Results The incidence rate of POAF was 26%, mostly occurred in the postoperative period from 1 d to 3 d. Compared with non POAF group, the age, the proportion of patients with age≥62.5 years or older, the proportion of patients with LAD≥35 mm, left ventricular end-diastolic diameter and perioperative transfusion of RBC were increased in POAF group, and data of mechanical ventilation time, ICU stay time and hospitalization time were prolonged, but the LVEF level decrease ( P<0.05). Among them, the elderly (≥62.5 years), increased LAD (≥35 mm), the higher perioperative transmission amount of RBC were the independent risk factors of POAF after ONCAB, and the higher LVEF was a protective factor for ONCAB. The optimal thresholds for age, RBC, LAD and LVEF were 62.5 years, 1U, 35.5 mm, and 0.34. Conclusion The occurrence of POAF after ONCAB is related with age (≥62.5 years old),LAD≥35 mm and perioperative transfusion of RBC, which can be used as clinically to predict the occurrence of POAF.
5.Clinical effects of coronary artery surgical treatment in uremic dialysis patients with coronary heart disease
Junwu CHAI ; Kai WANG ; Xiangrong KONG ; Honglei CHEN ; Fenlong XUE ; Weitie WANG ; Wei ZHOU
Tianjin Medical Journal 2017;45(9):973-976
Objective To summarize the experience of surgical treatment in patients with uremia and severe coronary artery disease, and reduce the perioperative risk thereof. Methods Sixteen chronic renal failure patients who were received haemodialysis and underwent coronary artery bypass grafting (CABG) during the period of February 2009 to December 2016 in Tianjin First Central Hospital were assessed in this retrospective study. Of the 16 patients, 8 patients and 6 patients were treated with off pump and on pump CABG respectively, one patient was treated with CABG and resection of ventricular aneurysm, and one patient was treated with CABG and tricuspid valve replacements. The renal function changes in preoperative and postoperative periods, 2-day and 1-week after surgery were observed. Echocardiography was used to evaluate cardiac function. The improvement of angina was recorded. Results Fourteen patients were successfully withdrawn from ventilator therapy within 24 h after surgery. The tracheal intubation was removed 65-hour after surgery in one patient. One patient died of multiple organ failure on the seventh day after surgery. The average length of ICU staying and in-hospital stay were (125.5 ± 21.6) h and (28.6 ± 7.4) days respectively. The serum creatinine (sCr) and blood urea nitrogen (BUN) were higher in two days after surgery than those before the operation (P < 0.05). Fifteen patients which followed up (the final follow-up date was February 2017) showing cardiac functionⅠ-Ⅱ, ejection fraction (EF)>0.40, and no angina occurred. Conclusion CABG is relatively safe for patients with end-stage renal disease and severe coronary artery disease. CABG can significantly eliminate angina symptoms with satisfactory clinical effect.
6.Incidence and evaluation of geriatric syndromes in hospitalized patients
Jie LI ; Xiuli CHENG ; Xiangrong GUAN ; Caixia XU ; Guodong WANG ; Jian KONG
Chinese Journal of Geriatrics 2017;36(3):266-268
Objective To examine the practice and value of comprehensive geriatric assessment(CGA)in geriatric care by conducting comprehensive evaluation of hospitalized elderly patients.Methods CGA was carried out in 91 hospitalized patients at our hospital from July 2015 to October 2015.Patients aged 65-75(6 cases),76-85(38 cases)and >85-99 years(47 cases)were assigned into three Groups.The incidence of geriatric syndromes ineach age group was calculated,and characteristics of geriatric syndromes among the patients were analyzed.ResultsFrailty had the highest incidence among all age groups 69(64.8%).In Group 65-75 years old,pain was mostfrequently reported 2(33.3%);in Group 76-85 years old,the three most frequent syndromes were frailty,dementiaand falls;in Group 85-99 years old,frailty,polypharracy and rnalnutrition occurred most often.Up to 37.4%% of the patients showed coexistence of 3-4 common geriatric syndromes,and only 14.2% of the patients had none Conclusions Frailty,dementia,falls,polypharrnacy,and malnutrition are the most common geriatric syndromes in hospitalized elderly patients.Coexistence of multiple geriatric syndromes is common among these patients.
7.Use of high-level HBV replication transgenic mice for evaluating drugs treating hepatitis B virus
Guangze LIU ; Xiangping KONG ; Xiangrong REN ; Xiumei LI ; Lianmei HU ; Lizhen HUANG ; Weiwang GU
Chinese Journal of Pathophysiology 1986;0(01):-
AIM:To study the high-level HBV replication transgenic mice for evaluation of drugs treating hepatitis B virus.METHODS:The HBV transgenic mice were treated respectively with lamivudine,large dose recombinant hepatitis B protein vaccine,?-1b interferon,siRNA to evaluate their pharmacodynamics and mechanism of action.RESULTS:HBV DNA titre was reduced significantly in transgenic mice which were treated with lamivudine(100 mg?kg-1?d-1),recombinant hepatitis B protein vaccine(HBsAg 6 ?g/mouse),?-1b interferon(50 ?g /mouse),respectively.Recombinant hepatitis B protein vaccine and ?-1b interferon promoted the level of IL-2 and IFN-? and increased the Elispot number of spleen cells secreting IFN-? in the treated transgenic mice.HBV transgenic mice were treated with RNAi expression vector pU6-siHBV against HBV through vena caudalis by hydrodynamics technique.Five days later,the level of serum HBsAg was reduced by 56.7% and the inhibition lasted at least 14 days.The HbcAg(+)cells were decreased obviously by immunohistochemistry detection in liver tissue,but the RNAi did not reduce the serum HBV DNA titre.CONCLUSION:These inbreeding high-level HBV replication transgenic mice are reliable and feasible for evaluating the anti-HBV drugs and have its economical and convenient superiority.
8.A case report of right coronary artery bypass grafting with completely reversed internal
Junwu CHAI ; Kai WANG ; Wei ZHOU ; Honglei CHEN ; Fenlong XUE ; Weitie WANG ; Rui MI ; Xiangrong KONG
Tianjin Medical Journal 2017;45(6):636-637
The incidence of dextrocardia is lower. The dextrocardia is often associated with congenital anatomical abnormalities. The patient with normal cardiac structure of dextrocardia and severe coronary heart disease that needs coronary artery bypasss is rarer. This article summarizes the perioperative management and surgical experience of dextrocardia with bypass surgery via a clinical case.
9.A prospective multicenter clinical trial study of a domestic HeartCon third-generation magnetic and hydrodynamic levitation LVAD for the treatment of 50 cases of end-stage heart failure
Xiaocheng LIU ; Chunsheng WANG ; Xinmin ZHOU ; Bin YANG ; Liangwan CHEN ; Qi AN ; Tianxiang GU ; Zhiyun XU ; Jinsong HUANG ; Xiangrong KONG ; Yongfeng SHAO
Chinese Journal of Thoracic and Cardiovascular Surgery 2023;39(5):273-278
Objective:To analyze and evaluate the safety and efficacy of a Chinese domestically manufactured Heart Con-type implantable third-generation magnetic and hydrodynamic levitation left ventricular assist device(LVAD) for the treatment of end-stage heart failure(ESHF), by reporting the results of eleven-center clinical trial on 50 cases.Methods:This study was a multicenter clinical trial, designed by means of prospective, multicenter and single-group target value. 50 subjects with ESHF were competitively enrolled and treated with HeartCon as the LVAD in eleven centers. The primary efficacy measure was survival, defined as either the subjects experiencing the transition to heart transplantation(HT) or myocardial recovery assisted by the device within 90 days, or as successfully assisted by the LVAD for full 90 days after implantation. The target survival rate was 60%, other observations included implantation success rate, mortality, pump failure needing replacement or emergency heart transplantation.Results:All enrolled 50 patients received LVAD implantation successfully, 46 survived with the pump for 90 days, 1 patient transitioned to heart transplantation, and 3 patients experienced pump thrombosis, within which 2 patients underwent pump replacement and continued to live with the pump for 90 days, and the other one received emergency heart transplantation. There were no dropout subjects. The survival rate at full 90 days after HeartCon implantation was 100%. The survival rates with pump in the full set analysis and the protocol set analysis were 96.00% and 95.92% respectively, which were higher than the target value of 60%. The differences were both statistically significant( P<0.05). Conclusion:The results of the multicenter clinical trial with the largest sample size in China using domestically manufactured third-generation LVAD has demonstrated that, HeartCon is a safe and effective LVAD to treat ESHF patients.
10.Combined heart and kidney transplantation: one case report
Junwu CHAI ; Kai WANG ; Xiangrong KONG ; Chunbo MO ; Wei ZHOU ; Honglei CHEN ; Fenlong XUE
Chinese Journal of Organ Transplantation 2018;39(3):145-148
Objective To summarize the outcomes and clinical experience of combined heart and kidney transplantation.Methods The clinical data of one case of combined heart and kidney transplantation were retrospectively analyzed.The kidney transplant was completed immediately after the heart transplant.The immunosuppressive therapy strategies included tacrolimus,corticosteroids and mycophenolate mofetil.Results For heart transplantation,heart cold ischemia time was 200 min,aorta blocking time was 136 min,and extracorporeal circulation time was 201 min.The kidney was transplanted to the right iliac fossa after heart transplantation.The endotracheal tube was removed 15 h after surgery.The patient was transferred to the general ward on the 8th day after surgery.The patient was discharged from the hospital at 27th day after surgery,the renal function was normal and no activity was restricted.Conclusion Reasonable perioperative management and selection of surgical methods are the keys to the success of combined heart and kidney transplantation.